Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Seelos Therapeutics stock | $3.08

Learn how to easily invest in Seelos Therapeutics stock.

Seelos Therapeutics, Inc
NASDAQ: SEEL - USD
BIOTECHNOLOGY
$2.20
-$0.05 (-2.22%)

Seelos Therapeutics, Inc is a biotechnology business based in the US. Seelos Therapeutics shares (SEEL) are listed on the NASDAQ and all prices are listed in US Dollars. Seelos Therapeutics employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Seelos Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SEEL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Seelos Therapeutics stock price (NASDAQ: SEEL)

Use our graph to track the performance of SEEL stocks over time.

Seelos Therapeutics shares at a glance

Information last updated 2021-07-28.
Latest market close$3.08
52-week range$0.56 - $6.60
50-day moving average $2.79
200-day moving average $3.60
Wall St. target price$9.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.81

Buy Seelos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Seelos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Seelos Therapeutics price performance over time

Historical closes compared with the close of $3.08 from 2021-05-28

1 week (2021-07-23) N/A
1 month (2021-07-02) 9.22%
3 months (2021-05-03) -47.35%
6 months (2021-01-30) N/A
1 year (2020-07-30) N/A
2 years (2019-07-30) N/A
3 years (2018-07-30) N/A
5 years (2016-07-30) N/A

Seelos Therapeutics financials

Gross profit TTM $-10,984,000
Return on assets TTM -67.21%
Return on equity TTM -211.8%
Profit margin 0%
Book value $0.32
Market capitalisation $243.8 million

TTM: trailing 12 months

Shorting Seelos Therapeutics shares

There are currently 4.0 million Seelos Therapeutics shares held short by investors – that's known as Seelos Therapeutics's "short interest". This figure is 19.5% down from 4.9 million last month.

There are a few different ways that this level of interest in shorting Seelos Therapeutics shares can be evaluated.

Seelos Therapeutics's "short interest ratio" (SIR)

Seelos Therapeutics's "short interest ratio" (SIR) is the quantity of Seelos Therapeutics shares currently shorted divided by the average quantity of Seelos Therapeutics shares traded daily (recently around 4.2 million). Seelos Therapeutics's SIR currently stands at 0.94. In other words for every 100,000 Seelos Therapeutics shares traded daily on the market, roughly 940 shares are currently held short.

However Seelos Therapeutics's short interest can also be evaluated against the total number of Seelos Therapeutics shares, or, against the total number of tradable Seelos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seelos Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Seelos Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.053% of the tradable shares (for every 100,000 tradable Seelos Therapeutics shares, roughly 53 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Seelos Therapeutics.

Find out more about how you can short Seelos Therapeutics stock.

Seelos Therapeutics share dividends

We're not expecting Seelos Therapeutics to pay a dividend over the next 12 months.

Have Seelos Therapeutics's shares ever split?

Seelos Therapeutics's shares were split on a 1:30 basis on 23 January 2019. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Seelos Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Seelos Therapeutics shares which in turn could have impacted Seelos Therapeutics's share price.

Seelos Therapeutics share price volatility

Over the last 12 months, Seelos Therapeutics's shares have ranged in value from as little as $0.5603 up to $6.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seelos Therapeutics's is 3.0918. This would suggest that Seelos Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Seelos Therapeutics overview

Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. .

Frequently asked questions

What percentage of Seelos Therapeutics is owned by insiders or institutions?
Currently 4.851% of Seelos Therapeutics shares are held by insiders and 26.812% by institutions.
How many people work for Seelos Therapeutics?
Latest data suggests 13 work at Seelos Therapeutics.
When does the fiscal year end for Seelos Therapeutics?
Seelos Therapeutics's fiscal year ends in December.
Where is Seelos Therapeutics based?
Seelos Therapeutics's address is: 300 Park Avenue, New York, NY, United States, 10022
What is Seelos Therapeutics's ISIN number?
Seelos Therapeutics's international securities identification number is: US81577F1093
What is Seelos Therapeutics's CUSIP number?
Seelos Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03832V109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site